Evidence map›Paper›PMID 31929803›Full record

ArticleAdvances in hematology2019

Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients.

M A ElBaiomy, S Aref, M El Zaafarany, Sara Atwa, Tamer Akl, Wafaa El-Beshbishi, Shaimaa El-Ashwah, L Ibrahim, M El-Ghonemy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

M A ElBaiomyMedical Oncology Unit, Mansoura University Oncology Center, Mansoura, Egypt.ORCID https://orcid.org/0000-0001-8702-7633
S ArefHematology Unit, Clinical Pathology Department, Mansoura University, Egypt.ORCID https://orcid.org/0000-0002-4822-5204
M El ZaafaranyMedical Oncology Unit, Mansoura University Oncology Center, Mansoura, Egypt.
Sara AtwaMedical Oncology Unit, Mansoura University Oncology Center, Mansoura, Egypt.
Tamer AklMedical Oncology Unit, Mansoura University Oncology Center, Mansoura, Egypt.
Wafaa El-BeshbishiClinical Oncology and Nuclear Medicine Department, Mansoura University, Egypt.
Shaimaa El-AshwahClinical Hematology Unit, Mansoura University Oncology Center, Mansoura, Egypt.
L IbrahimHematology Unit, Clinical Pathology Department, Mansoura University, Egypt.
M El-GhonemyHematology Unit, Clinical Pathology Department, Mansoura University, Egypt.ORCID https://orcid.org/0000-0003-1192-7162
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDeregulation of the Wnt signaling pathway had a role in haematological malignancies. Previous studies reported that lymphoid enhancer factor 1 (LEF1) expression and serum Galectin-3 level could affect clinical parameters and outcome in acute myeloid leukemia patients, but as far as we know, no study has addressed their combined effect on AML patients.

aimWe studied the expression of LEF1 by real-time qPCR and measured serum level of Gal.3 by ELISA technique in peripheral blood of 69 AML patients and correlated it with different clinicopathological criteria of patients, response, PFS and OS.

resultsWe found high expression (LEF1

conclusionWe conclude that high LEF1 expression was a favorable prognostic marker which can define AML patient risk and outcome independent from assessing the serum galectin.3 level.

Identifiers

PMID31929803
PMCPMC6935809
OpenAlexW2994768175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.